Godavari Biorefineries Q1 FY27 Preview: Key Ranges

What to watch before the Q1 FY27 results

Godavari Biorefineries is expected to report its Q1 FY27 results in the July-August 2026 window, in line with the regular quarterly earnings season for the June quarter. The stock’s current market price (CMP) is Rs 266, while the 12-month target range cited here is Rs 245-279. This preview compiles the estimate ranges and links them to the company’s recent reported numbers.

The estimates in this note are positioned as a trailing-growth framework, using Q1 FY26 as the base quarter and incorporating the latest year-on-year signal referenced from Q4 FY26. The idea is to frame a reasonable range rather than a single point forecast, given the variability visible across recent quarters.

The estimate framework cited in this preview

The article’s estimate approach starts from Q1 FY26 revenue of Rs 534 crore and Q1 FY26 net profit of Rs -16 crore. It also references the most recent reported quarter (Q4 FY26) as the latest data point, with revenue of Rs 570 crore and net profit of Rs 53 crore stated as the base for the estimates.

Alongside those rounded figures, the article also provides reported line items in lakh for Q4 FY26, which convert to crore values. Revenue from operations is shown at Rs 564.1 crore, total income at Rs 570.0 crore, and profit after tax (PAT) at Rs 52.9 crore. These numbers broadly align with the rounded Q4 FY26 figures cited earlier and help readers reconcile the scale of operations.

Godavari Biorefineries Q1 FY27 estimate ranges

The Q1 FY27 revenue estimate range in this preview is Rs 481-553 crore. The PAT estimate range is Rs -10 to -13 crore. The results date is indicated as July-August 2026.

The table below reproduces the estimate block as provided, including the year-on-year growth field shown alongside the ranges.

Recap of Q4 FY26: revenue, income, and PAT

Ahead of the Q1 FY27 print, Q4 FY26 provides the most recent reference point in the article. Revenue from operations for Q4 FY26 is listed at Rs 564.1 crore, up 22.67% versus Q3 FY26 at Rs 459.9 crore (QoQ) and down 2.66% versus Q4 FY25 at Rs 579.5 crore (YoY). Total income for Q4 FY26 is shown at Rs 570.0 crore, up 23.40% versus Q3 FY26 at Rs 461.9 crore and down 3.19% versus Q4 FY25 at Rs 588.8 crore.

PAT for Q4 FY26 is reported at Rs 52.9 crore, up 540.85% QoQ versus Q3 FY26 at Rs 8.3 crore and down 26.47% YoY versus Q4 FY25 at Rs 71.9 crore. Basic and diluted EPS for Q4 FY26 stood at Rs 10.33, compared with Rs 1.61 in Q3 FY26 and Rs 14.05 in Q4 FY25.

How the recent quarter-to-quarter pattern looks

The quarterly snapshot included in the source data shows a swing from losses in Sep 2025 and Jun 2025 to profitability in Dec 2025 and Mar 2026. For consolidated quarterly results, revenues are listed at Rs 533 crore (Jun 2025), Rs 431 crore (Sep 2025), Rs 460 crore (Dec 2025), and Rs 564 crore (Mar 2026). PAT over the same periods is Rs -16 crore, Rs -42 crore, Rs 8 crore, and Rs 53 crore.

Operating income also moved sharply across the same set, from Rs 6 crore (Jun 2025) and Rs -8 crore (Sep 2025) to Rs 43 crore (Dec 2025) and Rs 86 crore (Mar 2026). This variation is relevant context for why the preview uses ranges for Q1 FY27 rather than a single forecast.

Q1 FY26 base quarter: what the company reported

The estimate framework uses Q1 FY26 as the base quarter. For Q1 FY26, the article states total income of Rs 534.0 crore compared with Rs 525.3 crore in Q1 FY25. EBITDA for Q1 FY26 was Rs 6.5 crore versus Rs -9.5 crore in Q1 FY25, with an EBITDA margin of 1.2%.

Profit before tax (PBT) in Q1 FY26 is shown at Rs -22.3 crore versus Rs -41.6 crore in Q1 FY25. PAT was Rs -16.0 crore compared with Rs -26.1 crore in Q1 FY25, and PAT margin was -3.0%.

Full-year FY26: profit versus FY25 loss

For FY26, the company reported a profit of Rs 3.5 crore versus a loss of Rs 23.4 crore in FY25, as per the figures presented. EPS for FY26 is shown at Rs 0.69 compared with a negative Rs 5.11 in FY25.

A separate standalone FY26 profit figure is also listed at Rs 1.2 crore compared with a standalone loss of Rs 27.2 crore in FY25. These disclosures indicate that profitability has varied meaningfully between interim quarters, but the full-year direction cited is an improvement from FY25 to FY26.

Valuation markers: CMP versus the 12-month target range

With CMP at Rs 266 and the 12-month target range at Rs 245-279, the implied band spans both downside and upside around the current price. Relative to CMP, Rs 245 implies about 7.9% downside, while Rs 279 implies about 4.9% upside.

This preview does not provide a valuation multiple or explicit model drivers beyond the trailing-growth framing and the estimate ranges. Investors typically track how actual revenue and PAT compare with these bands, and whether the company sustains the improvement visible in Q4 FY26.

Market impact: what the Q1 FY27 print could change

The most direct market variable here is the gap between actual results and the stated estimate ranges: revenue of Rs 481-553 crore and PAT of Rs -10 to -13 crore. If the reported numbers fall outside these bands, it can reshape near-term expectations, particularly because the immediately preceding quarter (Q4 FY26) showed PAT of about Rs 53 crore.

Another factor to watch is whether revenue softness, if any, aligns with the year-on-year signals highlighted for Q4 FY26, where revenue from operations was down 2.66% YoY even as it improved sharply QoQ. The Q1 FY26 base quarter also had a low EBITDA margin (1.2%) and a PAT loss, which keeps attention on margin and cost lines.

Why this preview matters

The key takeaway from the data provided is that Godavari Biorefineries has shown sharp quarter-to-quarter swings in profitability across FY26, culminating in a strong Q4 FY26. Against that backdrop, the Q1 FY27 preview points to a revenue range below the Q1 FY26 base and a continued PAT loss range for Q1 FY27.

The July-August 2026 results window is the next concrete milestone cited. When the company announces the Q1 FY27 numbers, investors will be able to compare the actual revenue, PAT, and margins against both the Q1 FY26 base and the Q4 FY26 run-rate presented in this dataset.